ET-790

ET-790 is a potent, small-molecule dual inhibitor of Fms-like tyrosine kinase 3 (FLT3) and Interleukin-1 receptor-associated kinase 4 (IRAK4), originally developed by Eilean Therapeutics (acquired by Eli Lilly in January 2024). It is designed to treat Acute Myeloid Leukemia (AML) by targeting a broad spectrum of FLT3 mutations, including internal tandem duplications (ITD), tyrosine kinase domain (TKD) mutations such as D835, and the gatekeeper F691L mutation, which often confer resistance to first- and second-generation FLT3 inhibitors. By simultaneously inhibiting IRAK4, ET-790 aims to suppress the TLR/IL-1R (myddosome) signaling pathway, a known bypass mechanism that promotes cell survival and resistance in FLT3-mutant AML. This dual-targeting strategy is intended to provide deeper and more durable clinical responses compared to single-target FLT3 inhibitors.

Other names

FLT3/IRAK4 inhibitorpan-FLT3/IRAK4 inhibitor